Abstract: The present invention belongs to the field of medical technology and specifically relates to an active ingredient group for treating constipation. An active ingredient group for treating constipation, characterized in that the active ingredient group includes rhein, hesperetin, albiflorin, and magnolol. The key target combination of constipation includes RXRA, CYP1A1, CYP1A2 and PLA2G4. The active ingredient group for treating constipation provided in this application can effectively prevent and treat constipation by regulating bile acid secretion, steroid hormone biosynthesis, glycerophospholipid metabolism, and linoleic acid metabolism by establishing strong combination between the active ingredient group and the key target combination of constipation. This application also discloses the biomarkers for the diagnosis and treatment of constipation.

Abstract: The present invention belongs to the field of medical technology and specifically relates to an active ingredient group for treating UC. An active ingredient group for treating UC, characterized in that it uses an active ingredient group to act on key target combination of UC, and prevents and treats UC by regulating tryptophan metabolism, glycerolphospholipid metabolism, and linoleic acid metabolism. The active ingredient group for treating UC provided in this application can effectively prevent and treat UC by regulating tryptophan metabolism, glycerolphospholipid metabolism and linoleic acid metabolism by establishing strong combination between the active ingredient group and the key target combination of UC. This application also discloses the biomarkers for the diagnosis and treatment of UC.

Abstract: Provided herein is a method of diagnosing irritable bowel syndrome in a subject involving determining the amount of at least one of Ruminococcus gnavus, phenethylamine, tryptamine and tyramine in a fecal sample obtained from the subject. Also provided is a method of treating irritable bowel syndrome in a subject in need thereof involving the administration of a therapeutically effective amount of a trace amine-associated receptor 1 inhibitor.

Abstract: Provided herein is a method of diagnosing a metabolic disorder in a subject involving determining the amount of at least one of Ruminococcus gnavus, phenethylamine, and tryptamine in a fecal sample obtained from the subject. Also provided is a method of treating a metabolic disorder in a subject in need thereof involving the administration of a therapeutically effective amount of a trace amine-associated receptor 1 inhibitor.

Abstract: The present invention belongs to the technical field of pharmaceuticals, and particularly relates to a green and healthy medicine composition for preventing and treating inflammatory bowel disease. The medicine composition comprises: 15-25 g of roots of Codonopsis pilosula (Franch.) Nannf., 5-15 g of Atractylodes macrocephala Koidz., 15-25 g of Poria cocos (Schw.) Wolf, 1-10 g of Cornus officinalis Sieb. et Zucc., 1-10 g of Coptis chinensis Franch., 1-10 g of Curcuma Longa L., 5-15 g of Paederia scandens (Lour.) Merr., 5-15 g of Bletilla striata (Thunb.) Reichb.f., and 1-10 g of Glycyrrhiza uralensis Fisch. The solution disclosed by the present application has significant beneficial effect on the prevention and treatment of inflammatory bowel disease, and the herbs used in the present application are widely used traditional Chinese medicine products with no or low toxic effect; therefore, the green and healthy medicine composition has green, healthy and safe technical advantages.

Abstract: A method of treating a glucose-6-phosphate dehydrogenase deregulated disorder in a subject in need thereof, the method involving administering a therapeutically effective amount of oleanolic acid or a conjugate salt thereof or prodrug thereof to the subject. The glucose-6-phosphate dehydrogenase deregulated disorder can be BCL2 associated athanogene myofibrillar myopathy, amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, or Alzheimer disease.

Abstract: Provided herein are compounds useful in the treatment of inflammatory diseases, pharmaceutical compositions comprising the same, and methods of use and preparation thereof. The compounds exhibit inhibitory effects on the expression and secretion of pro-inflammatory cytokines, such as IL-1?, IL-6 and TNF-?.

Abstract: An herbal composition including Fructus Terminaliae Chebulae, Radix Paeoniae Lactiflorae, Cortex Magnoliae Officinalis, Rhizoma Corydalis Yanhusuo, Herba Polygoni Chinensis, Rhizoma Atractylodis Macrocephalae, and Semen coicis Lachryrna-jobi useful for treating diseases, such as inflammatory bowel disease, by increasing regulatory T cells in a subject in need thereof, methods for preparing of use and preparation thereof.

Abstract: Provided herein are compounds useful in the treatment of inflammatory diseases, pharmaceutical compositions comprising the same, and methods of use and preparation thereof. The compounds exhibit inhibitory effects on the expression and secretion of pro-inflammatory cytokines, such as IL-1?, IL-6 and TNF-?.

Abstract: Provided herein are Bradykinin-potentiating peptide chemotherapeutic drug conjugates useful as cancer therapeutics, pharmaceutical compositions comprising the same, and methods of preparation and use thereof.

Abstract: Provided is a combined pharmaceutical composition of HF and an Artemisia annua sesquiterpene lactone compound for treating cancers. The active ingredients of the combined pharmaceutical composition consist of HF and an Artemisia annua sesquiterpene lactone compound. HF and ATS have significant synergistic effect. The activity of the combined pharmaceutical of HF and ATS is comparable or even higher than that of the anti-cancer drug 5-FU.

Abstract: Provided is a combined pharmaceutical composition of HF and an Artemisia annua sesquiterpene lactone compound for treating cancers. The active ingredients of the combined pharmaceutical composition consist of HF and an Artemisia annua sesquiterpene lactone compound. HF and ATS have significant synergistic effect. The activity of the combined pharmaceutical of HF and ATS is comparable or even higher than that of the anti-cancer drug 5-FU.

Abstract: Cyclic peptide agonists toward human galanin receptor 2 (GalR2) and galanin receptor 3 (GalR3) based on hidden conformation of spexin solution structure for GalR2 and GalR3-related and spexin-deficient disorders are designed and synthesized. LH101, LH102, and LH101 (Ac) are potent spexin analogs with prolonged action, which can be used in the treatment of GalR2 and GalR3-related diseases and spexin-deficient disorders, such as obesity.

Abstract: Cyclic peptide agonists toward human galanin receptor 2 (GalR2) and galanin receptor 3 (GalR3) based on hidden conformation of spexin solution structure for GalR2 and GalR3-related and spexin-deficient disorders are designed and synthesized. LH101, LH102, and LH101 (Ac) are potent spexin analogs with prolonged action, which can be used in the treatment of GalR2 and GalR3-related diseases and spexin-deficient disorders, such as obesity.

Abstract: The present invention relates to an atom economic procedure of preparing iodoalkanes by hydroiodination of alkenes. In particular the present method features the generation of anhydrous hydrogen iodide from atomic hydrogen and iodine in situ by using transition metal precursor and phosphine ligandcatalyst.

Abstract: The present invention provides a slow and controlled released liposomal gel composition for subcutaneous administration comprises insulin or exenatide as active ingredient for reduction of blood sugar level and method of preparation thereof. Said controlled released composition has high bioavailability and is demonstrated to be able to sustain release therapeutically effective concentration of drug over a period of time and without rapid release of drug after initial administration. Method of preparing the controlled released composition of the present invention comprises the following steps: mixing insulin or exenatide, lipid and aqueous dispersion medium together; then mixing with poloxamer (e.g. F127 or P123) and/or gelatin and hyaluronic acid (HA) or the like gel solution so as to form a protective layer on surface of every lipid micro vesicles or nano-vesicles for use in intramuscular, abdominal and subcutaneous administration.

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt, hydrate or prodrug thereof for inhibiting Syk activity,

Abstract: This invention relates to the quick and efficient synthesis of anti-tumor or anti-cancer compounds. More particularly, it relates to the quick and efficient synthesis of anti-tumor or anti-cancer compounds comprising phenylacetophenone derivatives using oxabenzonorbornadienes with terminal alkynes.

Abstract: The present invention relates to chemical constituents of the hydro-alcoholic extract of root of Lasia spinosa (L.) Thwait. More particularly, it relates to the bioactive chemical composition of Lasia spinosa (L.) Thwait and its anticancer effect. The present invention has application in the treatment of human esophageal carcinoma.

Abstract: The present invention relates to an atom economic procedure of preparing iodoalkanes by hydroiodination of alkenes. In particular the present method features the generation of anhydrous hydrogen iodide from atomic hydrogen and iodine in situ by using transition metal precursor and phosphine ligandcatalyst.